Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy

We studied the serologic response to the BNT162b2 mRNA vaccine at four weeks after the second dose in patients with RRMS treated with rituximab with extended-interval dosing (n = 26). At four weeks, 73% of patients were seropositive. No patient without B cells at the first dose (n = 4) was seroposit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rico, Audrey, Ninove, Laetitia, Maarouf, Adil, Boutiere, Clémence, Durozard, Pierre, Demortiere, Sarah, Saba Villarroel, Paola Mariela, Amroun, Abdennour, Fourié, Toscane, de Lamballerie, Xavier, Pelletier, Jean, Audoin, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673883/
https://www.ncbi.nlm.nih.gov/pubmed/34925877
http://dx.doi.org/10.1177/20552173211062142
Descripción
Sumario:We studied the serologic response to the BNT162b2 mRNA vaccine at four weeks after the second dose in patients with RRMS treated with rituximab with extended-interval dosing (n = 26). At four weeks, 73% of patients were seropositive. No patient without B cells at the first dose (n = 4) was seropositive. Four of seven (57%) patients with B-cell proportion >0% and ≤5% were seropositive. All patients with B-cell proportion >5% (n = 15) were seropositive. In all patients, quantitative ELISA measures after vaccination were correlated with B-cell counts measured before vaccination. In patients receiving rituximab, seropositivity after BNT162b2 mRNA vaccination emerged only after B-cell repopulation.

Ejemplares similares